vmireavizВестник медицинского института «РЕАВИЗ». Реабилитация, Врач и ЗдоровьеBulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)2226-762X2782-1579РЕАВИЗ10.20340/vmi-rvz.2022.5.CLIN.8vmireaviz-536Research ArticleКлиническая медицинаClinical medicineРоль выявления мутаций в генах KRAS и NRAS для определения стратегии терапии при колоректальном ракеThe role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancerhttps://orcid.org/0000-0001-9779-5708ТороповскийА. Н.ToropovskiyA. N.

Тороповский Андрей Николаевич - кандидат медицинских наук, генеральный директор.

Ульяновск.

Andrey N. Tоrоpоvsky - candidate of medical sciences, General Director, SJ LTD.

Ulyanоvsk.

director@testgen.ruhttps://orcid.org/0000-0001-9762-3383НикитинА. Г.NikitinA. G.

Никитин Алексей Георгиевич - кандидат биологических наук, советник по науке.

Ульяновск.

Alexei G. Nikitin - Candidate of Biological Sciences, Science Advisor, TESTGEN LTD.

Ulyanоvsk.

https://orcid.org/0000-0002-4012-875XВикторовД. А.ViktorovD. A.

Викторов Денис Александрович - кандидат биологических наук, директор по науке.

Ульяновск.

Denis A. Viktorov - candidate of biological sciences, Director of Science, TESTGEN LTD.

Ulyanоvsk.

viktorov@testgen.ruhttps://orcid.org/0000-0002-4837-2554СоловьевА. В.Solov'evA. V.

Соловьев Алексей Вячеславович - руководитель отдела ПЦР-разработок.

Ульяновск.

Alexey V. Solovyov - head of PCR-development department, TESTGEN LTD.

Ulyanоvsk.

https://orcid.org/0000-0003-2993-4045ХузинаР. М.KhuzinaR. M.

Хузина Рузалия Маратовна - младший научный сотрудник, ООО «ТЕСТГЕН».

Ульяновск.

Ruzaliya M. Khuzina - junior researcher, TESTGEN LTD.

Ulyanоvsk.

https://orcid.org/0000-0002-8055-1958ПавловаО. Н.PavlovaO. N.

Павлова Ольга Николаевна - доктор биологических наук, доцент, научный сотрудник, ООО «ТЕСТГЕН»; заведующая кафедрой физиологии с курсом безопасности жизнедеятельности и медицины катастроф, СамГМУ.

Ульяновск; Самара.

Olga N. Pavlova - doctor of biological sciences, assistant professor, researcher, TESTGEN LTD; Head of the Department of Physiology with the Course of Life Safety and Disaster Medicine, Samara State Medical University.

Ulyanоvsk; Samara.

casiopeya13@mail.ruООО «ЭС ДЖИ»РоссияSJ LTDRussian FederationООО «ТЕСТГЕН»РоссияTESTGEN LTDRussian FederationООО «ТЕСТГЕН»; Самарский государственный медицинский университетРоссияTESTGEN LTD; Samara State Medical UniversityRussian Federation202231102022057481Copyright © Тороповский А.Н., Никитин А.Г., Викторов Д.А., Соловьев А.В., Хузина Р.М., Павлова О.Н., 20222022Тороповский А.Н., Никитин А.Г., Викторов Д.А., Соловьев А.В., Хузина Р.М., Павлова О.Н.Toropovskiy A.N., Nikitin A.G., Viktorov D.A., Solov'ev A.V., Khuzina R.M., Pavlova O.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestnik.reaviz.ru/jour/article/view/536

Колоректальный рак - одна из наиболее часто диагностируемых злокачественных опухолей у мужчин и женщин, представляющая собой высоко гетерогенную группу новообразований, состоящую из подклассов с различными молекулярными и клиническими характеристиками, и, как следствие, пациенты с разными типами опухолей нуждаются в применении разных протоколов лечения. Среди предиктивных факторов ответа на лечение у пациентов с метастатическим колоректальным раком наиболее изученными являются гены семейства RAS (KRAS, NRAS). Определение статуса RAS - это первый шаг в индивидуальном подборе лекарственной терапии у пациентов с метастатическим колоректальным раком. Пациенты с определенными мутациями в генах KRAS и NRAS являются резистентными к терапии анти-EGFR-препаратами и имеют медиану выживаемости ниже, чем при WT (wild type) генотипах, что говорит о негативном прогнозе в случае наличия мутаций.

Colorectal cancer is one of the most frequently diagnosed malignant tumors in men and women, which is a highly heterogeneous group of neoplasms consisting of subclasses with different molecular and clinical characteristics, and, as a consequence, patients with different types of tumors require different treatment protocols. Among the predictive factors of treatment response in patients with metastatic colorectal cancer, the most studied are the genes of the RAS family (KRAS, NRAS). Determination of RAS status is the first step in individual selection of drug therapy in patients with metastatic colorectal cancer. Patients with certain mutations in KRAS and NRAS genes are resistant to anti-EGFR therapy and have a lower median survival than WT (wild type) genotypes, indicating a negative prognosis in the presence of mutations.

колоректальный ракKRASNRASтаргетная терапияcolorectal cancerKRASNRAStargeted therapyReferencesДавыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014.Davydov M.I., Aksel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Vestnik RONC im. N.N. Blokhina = Bulletin of N.N. Blokhin Russian Cancer Research Center. 2014 (In Russ).Pancione M., Remo A., Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348. https://doi.org/10.1155/2012/509348Pancione M., Remo A., Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348. https://doi.org/10.1155/2012/509348Bishehsari F., Mahdavinia M., Vacca M. et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014; 20(20):6055-6072. https://doi.org/10.3748/wjg.v20.i20.6055Bishehsari F., Mahdavinia M., Vacca M. et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014; 20(20):6055-6072. https://doi.org/10.3748/wjg.v20.i20.6055Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):29-39. https://doi.org/10.1023/a:1025806911782Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):29-39. https://doi.org/10.1023/a:1025806911782Cohen R., Pudlarz T., Delattre J.F. et al. Molecular targets for the treatment of metastatic colorectal cancer. Cancers (Basel). 2020;12(9):2350. https://doi.org/10.3390/cancers12092350Cohen R., Pudlarz T., Delattre J.F. et al. Molecular targets for the treatment of metastatic colorectal cancer. Cancers (Basel). 2020;12(9):2350. https://doi.org/10.3390/cancers12092350Issa J.P. Colon Cancer: It's CIN or CIMP. Clin Cancer Res. 2008;14(19):5939-5940. https://doi.org/10.1158/1078-0432.CCR-08-1596Issa J.P. Colon Cancer: It's CIN or CIMP. Clin Cancer Res. 2008;14(19):5939-5940. https://doi.org/10.1158/1078-0432.CCR-08-1596Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009;656:85-106. https://doi.org/10.1007/978-1-4419-1145-2_8Kwong L.N., Dove W.F. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009;656:85-106. https://doi.org/10.1007/978-1-4419-1145-2_8Бровкина О.И., Никитин А.Г. Мутации в генах KRAS и NRAS как биомаркеры в терапии колоректального рака и основные методы их детекции. Клиническая практика. 2021;12(1):66-71. https://doi.org/10.17816/clinpract63875Brovkina O.I., Nikitin A.G. Mutations in KRAS and NRAS genes as biomarkers in colorectal cancer therapy and basic methods of their detection. Clinical Practice. 2021;12(1):66-71. https://doi.org/10.17816/clinpract63875Linardou H., Briasoulis E., Dahabreh I.J. et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev. 2011;37(3):221-233. https://doi.org/10.1016/j.ctrv.2010.07.008Linardou H., Briasoulis E., Dahabreh I.J. et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev. 2011;37(3):221-233. https://doi.org/10.1016/j.ctrv.2010.07.008Писарева Е.Е., Любченко Л.Н., Коваленко С.П., Шаманин В.А. Анализ мутаций в генах KRAS и BRAF при раке толстой и прямой кишки в российской популяции. Сибирский онкологический журнал. 2016;15(2):36-41. https://doi.org/10.21294/1814-4861-2016-15-2-36-41Pisareva E.E., Ljubchenko L.N., Kovalenko S.P., Shamanin V.A. Analysis of mutations in kras and braf genes in colorectal cancer in Russian patients. Siberian Journal of Oncology. 2016;15(2):36-41. (In Russ). https://doi.org/10.21294/1814-4861-2016-15-2-36-41Vaughn C.P., Zobell S.D., Furtado L.V. et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307-312. https://doi.org/10.1002/gcc.20854Vaughn C.P., Zobell S.D., Furtado L.V. et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50(5):307-312. https://doi.org/10.1002/gcc.20854Molina J.R., Adjei A.A. The Ras/Raf/MAPK Pathway. J Thorac Oncol Elsevier. 2006;1(1):7-9.Molina J.R., Adjei A.A. The Ras/Raf/MAPK Pathway. J Thorac Oncol Elsevier. 2006;1(1):7-9.Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR., ERB B2., ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-115.Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR., ERB B2., ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-115.Grothey A., Lenz H.J. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol. 2012;30(15):1735-1737. https://doi.org/10.1200/JCO.2011.40.4194Grothey A., Lenz H.J. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol. 2012;30(15):1735-1737. https://doi.org/10.1200/JCO.2011.40.4194Шубин В.П., Поспехова Н.И., Цуканов А.С., Рыбаков Е.Г., Панина М.В., Сушков О.И. и др. Частота и спектр мутаций в гене KRAS при раке толстой кишки разной локализации и раке анального канала. Медицинская генетика. 2014;13(5):3135.Shubin V.P., Pospekhova N.I., Tsukanov A.S., Rybakov E.G., Panina M.V., Sushkov O.I. et al. Frequency and spectrum KRAS mutations in different localization of colon cancer and anal cancer. Medicinskaagenetika. 2014;13(5):3135. (in Russ).Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008;28(6):742-754. https://doi.org/10.1592/phco.28.6.742Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008;28(6):742-754. https://doi.org/10.1592/phco.28.6.742Lievre A., Bachet J.B., Corre D.L. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-3995. https://doi.org/10.1158/0008-5472.CAN-06-0191Lievre A., Bachet J.B., Corre D.L. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-3995. https://doi.org/10.1158/0008-5472.CAN-06-0191Diaz L.A., Williams R., Wu J. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-540. https://doi.org/10.1038/nature11219Diaz L.A., Williams R., Wu J. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-540. https://doi.org/10.1038/nature11219Lampson B.L., Pershing N.L., Prinz J.A. et al. Rare codons regulate KRas oncogenesis. Curr Biol. 2013;23(1):70-75. https://doi.org/10.1016/j.cub.2012.11.031Lampson B.L., Pershing N.L., Prinz J.A. et al. Rare codons regulate KRas oncogenesis. Curr Biol. 2013;23(1):70-75. https://doi.org/10.1016/j.cub.2012.11.031Porru M., Pompili L., Caruso C. et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. https://doi.org/10.1186/s13046-018-0719-1Porru M., Pompili L., Caruso C. et al. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. https://doi.org/10.1186/s13046-018-0719-1Cox A.D., Fesik S.W., Kimmelman A.C. et al. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov. 2014;13(11):828-851. https://doi.org/10.1038/nrd4389Cox A.D., Fesik S.W., Kimmelman A.C. et al. Drugging the undruggable RAS: Mission Possible? Nat Rev Drug Discov. 2014;13(11):828-851. https://doi.org/10.1038/nrd4389Liu M., Sjogren A.K., Karlsson C. et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with KRAS-induced lung cancer. Proc Natl Acad Sci USA. 2010;107(14):6471-6476. https://doi.org/10.1073/pnas.0908396107Liu M., Sjogren A.K., Karlsson C. et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with KRAS-induced lung cancer. Proc Natl Acad Sci USA. 2010;107(14):6471-6476. https://doi.org/10.1073/pnas.0908396107Tejpar S., Celik I., Schlichting M. et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30(29):3570-3577. https://doi.org/10.1200/JCO.2012.42.2592Tejpar S., Celik I., Schlichting M. et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30(29):3570-3577. https://doi.org/10.1200/JCO.2012.42.2592Al-Mulla F., Keith W.N., Pickford I.R. et al. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer. 1999;24(4):306-14.Al-Mulla F., Keith W.N., Pickford I.R. et al. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer. 1999;24(4):306-14.Munoz-Bellvis L., Fontanillo C., Gonzalez-Gonzalez M. et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density singlenucleotide polymorphism arrays. Mod Pathol . 2012;25(4):590-601.Munoz-Bellvis L., Fontanillo C., Gonzalez-Gonzalez M. et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density singlenucleotide polymorphism arrays. Mod Pathol . 2012;25(4):590-601.Albanese I., Scibetta A.G., Migliavacca M. et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325(3):784-91.Albanese I., Scibetta A.G., Migliavacca M. et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun. 2004;325(3):784-91.Zauber P., Sabbath-Solitare M,. Marotta S.P., Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003;56(3):137-40.Zauber P., Sabbath-Solitare M,. Marotta S.P., Bishop DT. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003;56(3):137-40.Loupakis F., Pollina L., Stasi I. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol . 2009;27(16):2622-9.Loupakis F., Pollina L., Stasi I. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol . 2009;27(16):2622-9.Scartozzi M., Bearzi I., Berardi R. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772-8.Scartozzi M., Bearzi I., Berardi R. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772-8.Italiano A., Saint-Paul M.C., Caroli Bosc F.X. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005;16(9):1503-7.Italiano A., Saint-Paul M.C., Caroli Bosc F.X. et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005;16(9):1503-7.Etienne-Grimaldi M.C., Formento J.L., Francoual M. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830-5.Etienne-Grimaldi M.C., Formento J.L., Francoual M. et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830-5.Tougeron D., Lecomte T., Pages J.C. et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24(5):1267-73.Tougeron D., Lecomte T., Pages J.C. et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24(5):1267-73.Baas J.M., Krens L.L., Guchelaar H.J. et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16(9):1239-49.Baas J.M., Krens L.L., Guchelaar H.J. et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16(9):1239-49.Mostert B., Jiang Y., Sieuwerts A.M. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130-41.Mostert B., Jiang Y., Sieuwerts A.M. et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130-41.Leder K., Foo J., Skaggs B. et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of preexisting resistance in chronic myeloid leukemia. PLoS One. 2011;6(11):e27682.Leder K., Foo J., Skaggs B. et al. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of preexisting resistance in chronic myeloid leukemia. PLoS One. 2011;6(11):e27682.Oltedal S., Aasprong O.G., M0ller J.H. et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis. 2011;26(10):1271-7.Oltedal S., Aasprong O.G., M0ller J.H. et al. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. Int J Colorectal Dis. 2011;26(10):1271-7.Ramaswamy S., Ross K.N., Lander E.S.,Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49-54.Ramaswamy S., Ross K.N., Lander E.S.,Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33(1):49-54.McGranahan N., Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15-26 .McGranahan N., Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15-26 .Misale S., Yaeger R., Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(404):532-6.Misale S., Yaeger R., Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(404):532-6.Fedyanin M.Yu., Elsnukaeva H.H.-M., Tjulandin S.A. Heterogeneity and clonal evolution of colorectal cancer. Advances in molecular oncology. 2017;4:24-34. https://doi.org/10.17650/2313-805X-2017-4-1-24-34Fedyanin M.Yu., Elsnukaeva H.H.-M., Tjulandin S.A. Heterogeneity and clonal evolution of colorectal cancer. Advances in molecular oncology. 2017;4:24-34. https://doi.org/10.17650/2313-805X-2017-4-1-24-34

The authors declare that there are no conflicts of interest present.